AU2016303614A1 - Methods of preparing 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diols and 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diamines - Google Patents

Methods of preparing 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diols and 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diamines Download PDF

Info

Publication number
AU2016303614A1
AU2016303614A1 AU2016303614A AU2016303614A AU2016303614A1 AU 2016303614 A1 AU2016303614 A1 AU 2016303614A1 AU 2016303614 A AU2016303614 A AU 2016303614A AU 2016303614 A AU2016303614 A AU 2016303614A AU 2016303614 A1 AU2016303614 A1 AU 2016303614A1
Authority
AU
Australia
Prior art keywords
compound
formula
reacting
pct
give
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2016303614A
Other languages
English (en)
Inventor
Shijie Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agios Pharmaceuticals Inc
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of AU2016303614A1 publication Critical patent/AU2016303614A1/en
Priority to AU2021200494A priority Critical patent/AU2021200494A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
AU2016303614A 2015-08-05 2016-08-04 Methods of preparing 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diols and 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diamines Abandoned AU2016303614A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2021200494A AU2021200494A1 (en) 2015-08-05 2021-01-27 Methods of preparing 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diols and 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diamines

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562201546P 2015-08-05 2015-08-05
US62/201,546 2015-08-05
PCT/US2016/045553 WO2017024134A1 (en) 2015-08-05 2016-08-04 Methods of preparing 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diols and 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diamines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021200494A Division AU2021200494A1 (en) 2015-08-05 2021-01-27 Methods of preparing 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diols and 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diamines

Publications (1)

Publication Number Publication Date
AU2016303614A1 true AU2016303614A1 (en) 2018-02-15

Family

ID=56684781

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016303614A Abandoned AU2016303614A1 (en) 2015-08-05 2016-08-04 Methods of preparing 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diols and 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diamines
AU2021200494A Abandoned AU2021200494A1 (en) 2015-08-05 2021-01-27 Methods of preparing 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diols and 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diamines

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2021200494A Abandoned AU2021200494A1 (en) 2015-08-05 2021-01-27 Methods of preparing 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diols and 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diamines

Country Status (8)

Country Link
US (1) US9751863B2 (enExample)
EP (1) EP3331866B1 (enExample)
JP (2) JP6816106B2 (enExample)
CN (1) CN108349933A (enExample)
AU (2) AU2016303614A1 (enExample)
CA (1) CA2993615A1 (enExample)
MX (1) MX365590B (enExample)
WO (1) WO2017024134A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3200800A1 (en) 2014-09-29 2017-08-09 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2016126798A1 (en) 2015-02-04 2016-08-11 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
EP3331866B1 (en) * 2015-08-05 2023-07-26 Les Laboratoires Servier Methods of preparing a 6-heteroaryl-1,3,5-triazine-2,4-diol and a 6-heteroaryl-1,3,5-triazine-2,4-diamine
MX381582B (es) 2015-10-15 2025-03-12 Celgene Corp Terapia de combinacion para el tratamiento de neoplasias malignas.
CA3001599A1 (en) 2015-10-15 2017-04-20 Agios Pharmaceuticals, Inc. Combination therapy for treating malignancies
IL298663A (en) 2015-12-04 2023-01-01 Agios Pharmaceuticals Inc Methods for treating acute myeloid leukemia characterized by the presence of a mutant allele of idh2 and the absence of a mutant allele of nras
WO2017146795A1 (en) 2016-02-26 2017-08-31 Agios Pharmaceuticals, Inc. Idh1 inhibitors for the treatment of haematological malignancies and solid tumours
JP2019529534A (ja) 2016-09-07 2019-10-17 セルジーン コーポレイション 錠剤組成物
EP3618828B1 (en) 2017-05-05 2023-11-01 Memorial Sloan Kettering Cancer Center Methods of treatment of myeloproliferative neoplasm
US20220017489A1 (en) 2018-11-02 2022-01-20 Celgene Corporation Solid dispersions for treatment of cancer
US20220017490A1 (en) 2018-11-02 2022-01-20 Celgene Corporation Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof
US12215094B2 (en) 2018-11-02 2025-02-04 Celgene Corporation Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol
WO2021097160A1 (en) 2019-11-14 2021-05-20 Celgene Corporation Pediatric formulations for treatment of cancer
CN111592524B (zh) * 2020-05-20 2023-11-17 温州市天聚万迅信息科技有限公司 恩西德尼的制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2390529A (en) 1942-02-03 1945-12-11 Ernst A H Friedheim Hydrazino-1,3,5-triazino derivatives of substituted phenylarsenic compounds
JPS5170779A (ja) * 1974-12-17 1976-06-18 Nippon Shinyaku Co Ltd Shinkinaguanamidoruino seiho
JPS58186682A (ja) 1982-04-27 1983-10-31 日本化薬株式会社 セルロ−ス又はセルロ−ス含有繊維材料の染色法
DE3512630A1 (de) 1985-04-06 1986-10-23 Hoechst Ag, 6230 Frankfurt Verfahren zum faerben oder bedrucken von cellulosefasern oder cellulosemischfasern
ATE130882T1 (de) 1990-07-12 1995-12-15 Ciba Geigy Ag Verfahren zur photochemischen und thermischen stabilisierung von polyamid-fasermaterialien.
JPH11158073A (ja) 1997-09-26 1999-06-15 Takeda Chem Ind Ltd アデノシンａ３拮抗剤
EP1187825A1 (en) 1999-06-07 2002-03-20 Shire Biochem Inc. Thiophene integrin inhibitors
HUE029020T2 (en) 2002-07-18 2017-02-28 Janssen Pharmaceutica Nv Substituted triazine kinase inhibitors
EP2152676B1 (en) 2007-04-30 2013-04-03 ProMetic BioSciences Inc. "triazine derivatives, compositions containing such derivatives, and methods of treatment of cancer and autoimmune diseases using such derivatives"
GB0805477D0 (en) 2008-03-26 2008-04-30 Univ Nottingham Pyrimidines triazines and their use as pharmaceutical agents
US20120238576A1 (en) 2009-06-08 2012-09-20 California Capital Equity, Llc Triazine Derivatives and their Therapeutical Applications
LT2800743T (lt) * 2012-01-06 2018-06-25 Agios Pharmaceuticals, Inc. Terapiškai aktyvūs junginiai ir jų panaudojimo būdai
CN104169260A (zh) 2012-03-09 2014-11-26 卡尔那生物科学株式会社 新三嗪衍生物
ES2807582T3 (es) 2013-07-11 2021-02-23 Agios Pharmaceuticals Inc Compuestos N,6-bis(aril o heteroaril)-1,3,5-triazina-2,4-diamina como inhibidores de mutantes IDH2 para el tratamiento del cáncer
WO2015003360A2 (en) * 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015017821A2 (en) 2013-08-02 2015-02-05 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
EP3200800A1 (en) 2014-09-29 2017-08-09 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2016126798A1 (en) 2015-02-04 2016-08-11 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
EP3331866B1 (en) * 2015-08-05 2023-07-26 Les Laboratoires Servier Methods of preparing a 6-heteroaryl-1,3,5-triazine-2,4-diol and a 6-heteroaryl-1,3,5-triazine-2,4-diamine

Also Published As

Publication number Publication date
MX365590B (es) 2019-06-07
AU2021200494A1 (en) 2021-03-11
US9751863B2 (en) 2017-09-05
CA2993615A1 (en) 2017-02-09
EP3331866B1 (en) 2023-07-26
EP3331866A1 (en) 2018-06-13
JP2018528182A (ja) 2018-09-27
CN108349933A (zh) 2018-07-31
JP6816106B2 (ja) 2021-01-20
WO2017024134A1 (en) 2017-02-09
US20170037031A1 (en) 2017-02-09
JP2021063097A (ja) 2021-04-22
MX2018001424A (es) 2018-08-01

Similar Documents

Publication Publication Date Title
US9751863B2 (en) Therapeutically active compounds and their methods of use
AU2012269648B2 (en) Therapeutically active compositions and their methods of use
TWI759251B (zh) 治療活性化合物及其使用方法
EP3019490B1 (en) N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer
JP7082256B1 (ja) ５－ヘテロアリール－１ｈ－ピラゾール－３－アミン誘導体
TWI757312B (zh) 作為異檸檬酸脫氫酶抑制劑的化合物及其應用
EP4056563A1 (en) Compound as shp2 inhibitor and use thereof
AU2014289745B2 (en) Therapeutically active compounds and their methods of use
KR20220118500A (ko) 치환 직쇄 스피로 유도체
JP7207634B2 (ja) Ｐ２ｘ３及び／又はｐ２ｘ２／３受容体アンタゴニスト、それを含む医薬組成物及びその使用
AU2013207289A1 (en) Therapeutically active compounds and their methods of use
JP2017057221A (ja) 治療活性組成物およびそれらの使用方法
AU2012298813A1 (en) Inhibitors of Nedd8-activating enzyme
CN111377873B (zh) 氨基嘧啶化合物及其制备方法和用途
KR102566237B1 (ko) 사이클로올레핀 치환된 헤테로방향족 화합물 및 그의 용도
JP2022528919A (ja) Ｍａｌｔ１阻害剤としての尿素誘導体
EP4105207A1 (en) Quinolyl phosphine oxide compound, and composition and application thereof
CN105517996A (zh) 治疗活性化合物及其使用方法
TW202610644A (zh) Cbl-b抑制劑的前藥化合物
WO2026017106A1 (zh) 一种Cbl-b抑制剂的前药化合物
HK40064179A (en) Piperazine amide derivative, preparation method therefor, and use thereof in medicine
EA044101B1 (ru) Циклоолефиновые замещённые гетероароматические соединения и их применение
CN116783195A (zh) N-苯基氨基羰基吡啶基-、嘧啶基和苯并-托烷作为gpr65的调节剂
HK40077066A (zh) 喹啉基膦氧化合物及其组合物和用途
HK40027076A (en) Cycloolefin substituted heteroaromatic compounds and their use

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted